Literature DB >> 12631066

GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury.

Prabal K Chatterjee1, Nimesh S A Patel, Ahila Sivarajah, Espen O Kvale, Laura Dugo, Salvatore Cuzzocrea, Paul A J Brown, Keith N Stewart, Helder Mota-Filipe, Domenico Britti, Muhammad M Yaqoob, Christoph Thiemermann.   

Abstract

BACKGROUND: Generation of nitric oxide (NO) by inducible nitric oxide synthase (iNOS) may contribute to renal ischemia/reperfusion (I/R) injury. The aim of this study was to investigate the effects of GW274150, a novel, highly selective, potent and long-acting inhibitor of iNOS activity in rat and mouse models of renal I/R.
METHODS: Rats were administered GW274150 (5 mg/kg intravenous bolus administered 30 minutes prior to I/R) and subjected to bilateral renal ischemia (45 minutes) followed by reperfusion (6 hours). Serum and urinary indicators of renal dysfunction, tubular and reperfusion injury were measured, specifically, serum urea, creatinine, aspartate aminotransferase (AST) and N-acetyl-beta-d-glucosaminidase (NAG) enzymuria. In addition, renal sections were used for histologic scoring of renal injury and for immunologic evidence of nitrotyrosine formation and poly [adenosine diphosphate (ADP)-ribose] (PAR). Nitrate levels were measured in rat plasma using the Griess assay. Mice (wild-type, administered 5 mg/kg GW274150, and iNOS-/-) were subjected to bilateral renal ischemia (30 minutes) followed by reperfusion (24 hours) after which renal dysfunction (serum urea, creatinine), renal myeloperoxidase (MPO) activity and malondialdehyde (MDA) levels were measured.
RESULTS: GW274150, administered prior to I/R, significantly reduced serum urea, serum creatinine, AST, and NAG indicating reduction of renal dysfunction and injury caused by I/R. GW274150 reduced histologic evidence of tubular injury and markedly reduced immunohistochemical evidence of nitrotyrosine and PAR formation, indicating reduced peroxynitrite formation and poly (ADP-ribose) polymerase (PARP) activation, respectively. GW274150 abolished the rise in the plasma levels of nitrate (indicating reduced NO production). GW274150 also reduced the renal dysfunction in wild-type mice to levels similar to that observed in iNOS-/- mice subjected to I/R. Renal MPO activity and MDA levels were significantly reduced in wild-type mice administered GW274150 and iNOS-/- mice subjected to renal I/R, indicating reduced polymorphonuclear leukocyte (PMN) infiltration and lipid peroxidation.
CONCLUSIONS: These results suggest that (1). an enhanced formation of NO by iNOS contributes to the pathophysiology of renal I/R injury and (2). GW274150 reduces I/R injury of the kidney. We propose that selective inhibitors of iNOS activity may be useful against renal dysfunction and injury associated with I/R of the kidney.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12631066     DOI: 10.1046/j.1523-1755.2003.00802.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  35 in total

1.  Ischaemic/reperfusion injury: Role of infliximab.

Authors:  Atul Bagul
Journal:  World J Transplant       Date:  2012-06-24

Review 2.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

3.  GW274150 and GW273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo.

Authors:  Wendy K Alderton; Anthony D R Angell; Caroline Craig; John Dawson; Edward Garvey; Salvador Moncada; Jayne Monkhouse; Daryl Rees; Linda J Russell; Rachel J Russell; Sheila Schwartz; Neil Waslidge; Richard G Knowles
Journal:  Br J Pharmacol       Date:  2005-06       Impact factor: 8.739

Review 4.  Delayed graft function in the kidney transplant.

Authors:  A Siedlecki; W Irish; D C Brennan
Journal:  Am J Transplant       Date:  2011-09-19       Impact factor: 8.086

5.  Noncleavable poly(ADP-ribose) polymerase-1 regulates the inflammation response in mice.

Authors:  Virginie Pétrilli; Zdenko Herceg; Paul O Hassa; Nimesh S A Patel; Rosanna Di Paola; Ulrich Cortes; Laura Dugo; Helder-Mota Filipe; Christoph Thiemermann; Michael O Hottiger; Salvatore Cuzzocrea; Zhao-Qi Wang
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

Review 6.  Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury.

Authors:  Suzanne Heemskerk; Rosalinde Masereeuw; Frans G M Russel; Peter Pickkers
Journal:  Nat Rev Nephrol       Date:  2009-09-29       Impact factor: 28.314

Review 7.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

8.  Differences in immunolocalization of Kim-1, RPA-1, and RPA-2 in kidneys of gentamicin-, cisplatin-, and valproic acid-treated rats: potential role of iNOS and nitrotyrosine.

Authors:  Jun Zhang; Peter L Goering; Parvaneh Espandiari; Martin Shaw; Joseph V Bonventre; Vishal S Vaidya; Ronald P Brown; Joe Keenan; Cormac G Kilty; Nakissa Sadrieh; Joseph P Hanig
Journal:  Toxicol Pathol       Date:  2009-06-17       Impact factor: 1.902

9.  Poly(ADP-ribose) polymerase-1 regulates the progression of autoimmune nephritis in males by inducing necrotic cell death and modulating inflammation.

Authors:  Neelakshi R Jog; Joudy-Ann Dinnall; Stefania Gallucci; Michael P Madaio; Roberto Caricchio
Journal:  J Immunol       Date:  2009-06-01       Impact factor: 5.422

Review 10.  Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review.

Authors:  Prabal K Chatterjee
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-22       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.